Objective:To compare postural stability and balance in different tasks between people with and without chronic, non-specific low back pain (CNLBP).Methods:Twenty patients with CNLBP formed the study′s CNLBP group, while 25 healthy counterparts were chosen as a normal group. Both groups were tested for their ability to standing on one leg with their eyes closed (the SOLEC test), for postural balance, for postural stability (PST), and had their limits of stability (LOS) time determined. The results were compared.Results:Compared to the normal group, the CNLBP group showed a significant difference in left-right weight-bearing in a bipedal semi-squat and in two-legged alternate standing. Shifting the center of gravity in bipedal standing revealed significant differences in LOS time, anterior-posterior stability index (APSI), mediolateral stability index (MLSI) and overall stability. In bipedal standing with the eyes closed there were significant differences in APSI, MLSI and OSI observed. On average, the CNLBP group had significantly shorter SOLEC and LOS times on the left and rear left sides.Conclusions:The CNLBP patients had some postural control deficits compared to their healthy counterparts and were less able to maintain static balance on their left leg and dynamic balance. They were less able to maintain postural balance in a bipedal semi-squat and during alternate leg standing. They are at greater risk of falling when moving the body′s center of gravity to the left or the rear left side.

Objective:To compare postural stability and balance in different tasks between people with and without chronic, non-specific low back pain (CNLBP).Methods:Twenty patients with CNLBP formed the study′s CNLBP group, while 25 healthy counterparts were chosen as a normal group. Both groups were tested for their ability to standing on one leg with their eyes closed (the SOLEC test), for postural balance, for postural stability (PST), and had their limits of stability (LOS) time determined. The results were compared.Results:Compared to the normal group, the CNLBP group showed a significant difference in left-right weight-bearing in a bipedal semi-squat and in two-legged alternate standing. Shifting the center of gravity in bipedal standing revealed significant differences in LOS time, anterior-posterior stability index (APSI), mediolateral stability index (MLSI) and overall stability. In bipedal standing with the eyes closed there were significant differences in APSI, MLSI and OSI observed. On average, the CNLBP group had significantly shorter SOLEC and LOS times on the left and rear left sides.Conclusions:The CNLBP patients had some postural control deficits compared to their healthy counterparts and were less able to maintain static balance on their left leg and dynamic balance. They were less able to maintain postural balance in a bipedal semi-squat and during alternate leg standing. They are at greater risk of falling when moving the body′s center of gravity to the left or the rear left side.

Objective To observe the clinical effect of Yi'naokang Capsules combined with Donepezil Hydrochloride Tablets in treating post-stroke cognitive impairment(PSCI).Methods 110 patients who met the diagnostic criteria of PSCI in the outpatient department were included.According to the random number table method,the patients were divided into trial group and control group,with 55 cases in each group.Patients in control group were treated with routine western medicine,including the treatment of Donepezil Hydrochloride Tablets and secondary prevention of stroke such as lowering blood pressure,lowering blood lipid,lowering blood glucose and anti-platelet aggregation.The trial group was treated with Yi'naokang Capsules on the basis of the treatment in control group,and both groups were treated for 6 months.Before and after 6 months of treatment,the cognitive function of patients was evaluated by the Montreal Cognitive Assessment(MoCA)scale.The activity of daily living(ADL)scale was used to evaluate the ability of daily living,and the severity of cerebral white matter lesions was evaluated by Fazekas scale,and the adverse reactions were also observed.Results After 6 months of treatment,the total score of the MoCA,the scores of visual space and executive function,attention,delayed recall and the ADL of the two groups were all improved(P＜0.05),and the improvement degree of the trial group was better than that of the control group(P＜0.05).The Fazekas score of the trial group after treatment was no significant difference when compared with that before treatment(P＞0.05),but it increased in the control group after treatment(P＜0.05),and the effect of delaying white matter lesion in the trial group was better than that in the control group(P＜0.05).Conclusion Yi'naokang Capsules combined with Donepezil Hydrochloride Tablets are superior to Donepezil alone in the treatment of PSCI,which can safely and effectively improve the cognitive function and daily living ability of patients,as well as prolong the progress of white matter lesions.

Objective To analyze the effect of Xuebijing injection on inflammatory response in patients after hepatobiliary and pancreatic surgeries, and to evaluate its safety and clinical value. Methods A retrospective cohort study was conducted. 708 patients received hepatobiliary and pancreatic surgeries of Nanfang Hospital, Southern Medical University from January 2015 to September 2017 were enrolled and divided into Xuebijing treatment group and conventional treatment group according to whether they were treated with Xuebijing injection or not. The inflammatory response indexes included white blood cell count (WBC), neutrophil (NE), C-reactive protein (CRP), body temperature, which were compared between the two groups at 1, 3, and 5 days after operation. The incidence of adverse reactions, the length of postoperative hospital stays and hospitalization costs were compared. Results A total of 209 patients were prescribed with Xuebijing injection, and 499 patients were allocated into conventional treatment group. The two groups were stratified by liver, biliary and pancreatic surgery types, and further 1:1 propensity score matching was performed. After propensity score match, 189 patients were included in each group, with 101, 46, and 42 patients undergoing liver, biliary, and pancreas surgery, respectively. There were no significant differences in baseline data such as gender, age and inflammatory response indexes before surgery between the two groups. In both groups, the WBC and NE showed a gradual decline after operation, CRP were increased gradually and then decreased after 3 days. Compared with the conventional treatment group, Xuebijing treatment group showed obvious anti-inflammatory effect from 3 days after operation [WBC (×109/L): 10.1±4.0 vs. 11.0±3.5, NE: 0.71±0.10 vs. 0.76±0.12, CRP (mg/L): 73.1±38.7 vs. 82.2±41.8, all P < 0.05]. On the 5th day, it still showed a strong anti-inflammatory trend [WBC (×109/L): 7.0±2.8 vs. 7.9±2.6, NE: 0.62±0.10 vs. 0.68±0.12, CRP (mg/L): 43.4±31.0 vs. 50.9±25.3, all P < 0.05]. The cases of postoperative fever in the Xuebijing treatment group were significantly less than that in the conventional treatment group (cases:98 vs. 119, χ2＝4.711, P＝0.029). There was no significant different in the total incidence of adverse drug reactions such as rash, nausea and vomiting (5.0% vs. 3.2%), the length of postoperative hospital stays [days: 9.3 (6.1, 13.5) vs. 9.1 (5.5, 13.3)] and hospitalization costs [wanyuan: 5.8 (3.6, 9.5) vs. 5.7 (3.5, 9.8)] between Xuebijing treatment group and conventional treatment group (all P > 0.05). Conclusions Xuebijing injection has a good anti-inflammatory effect on patients undergoing hepatobiliary and pancreatic surgeries. Xuebijing injection has good safety and can be applied to the prevention and treatment of excessive inflammatory reaction after hepatobiliary and pancreatic surgeries.